AIRFLOW-3 Trial of Targeted Lung Denervation Assigns 100th Patient

AIRFLOW-3 Trial of Targeted Lung Denervation Assigns 100th Patient

303685

AIRFLOW-3 Trial of Targeted Lung Denervation Assigns 100th Patient

One hundred patients have been randomly assigned in Nuvaira’s pivotal AIRFLOW-3 clinical trial that will investigate the efficacy and safety of targeted lung denervation (TLD) to reduce exacerbations, or episodes of symptom worsening, of chronic obstructive pulmonary disease (COPD) in patients on optimal medical care. Because of the COVID-19 pandemic, most of the trial’s activities were put on hold until June last year, when the Medical University of South Carolina became the first trial site…

You must be logged in to read/download the full post.